Journal: Journal of pharmaceutical and biomedical analysis

Article Title: Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS

doi: 10.1016/j.jpba.2017.02.018

Figure Lengend Snippet: Representative chromatograms of: A) abiraterone (m/z 350.0>156.0 ; 8.0 min) added to control plasma at the LLOQ concentration of 1 ng/mL (top trace with an offset of 300 counts) and control human plasma (bottom trace); B) bicalutamide (m/z 431.0>217.0; 4.1 min) added to control plasma at the LLOQ concentration of 1 ng/mL (top trace with an offset of 300 counts) and control human plasma (bottom trace); C) enzalutamide (m/z 467.0>211.0; 5.7 min) added to control plasma at the LLOQ concentration of 100 ng/mL (top trace with an offset of 500 counts) and control human plasma (bottom trace); D) N-desmethyl enzalutamide (m/z 453.0>197.0; 4.8 min) added to control plasma at the LLOQ concentration of 100 ng/mL (top trace with an offset of 300 counts) and control human plasma (bottom trace); E) [D4]-abiraterone internal standard (m/z 354.0>160.0; 8.0 min) added to control plasma at a concentration of 20 ng/mL (top trace with an offset of 300 counts) and control human plasma (bottom trace); F) [D4]-bicalutamide internal standard (m/z 435.0>221.0; 4.1 min) added to control plasma at a concentration of 10 ng/mL (top trace with an offset of 300 counts) and control human plasma (bottom trace); G) [D6]-enzalutamide (m/z 471.0>215.0; 5.7 min) added to control plasma at a concentration of 20 ng/mL (top trace with an offset of 500 counts) and control human plasma (bottom trace); H) [D6]-N-desmethyl enzalutamide (m/z 457.0>201.0; 4.8 min) added to control plasma at a concentration of 20 ng/mL (top trace with an offset of 300 counts) and control human plasma (bottom trace).

Article Snippet: 2.1 Chemicals and reagents Abiraterone, bicalutamide, N-desmethyl enzalutamide, enzalutamide, [D 4 ]-abiraterone, [D 4 ]-bicalutamide, were purchased from Toronto Research Chemicals (Toronto, Canada).

Techniques: Concentration Assay

Journal: Journal of pharmaceutical and biomedical analysis

Article Title: Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS

doi: 10.1016/j.jpba.2017.02.018

Figure Lengend Snippet: Assay performance data for the quantitation of LLOQ, QCL, QCM and QCH for all analytes

Article Snippet: 2.1 Chemicals and reagents Abiraterone, bicalutamide, N-desmethyl enzalutamide, enzalutamide, [D 4 ]-abiraterone, [D 4 ]-bicalutamide, were purchased from Toronto Research Chemicals (Toronto, Canada).

Techniques: Quantitation Assay, Concentration Assay, Intra Assay, Inter Assay

Journal: Journal of pharmaceutical and biomedical analysis

Article Title: Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS

doi: 10.1016/j.jpba.2017.02.018

Figure Lengend Snippet: Recoveries of analytes from human plasma and their respective matrix effects in human plasma, with coefficients of variation (CV)

Article Snippet: 2.1 Chemicals and reagents Abiraterone, bicalutamide, N-desmethyl enzalutamide, enzalutamide, [D 4 ]-abiraterone, [D 4 ]-bicalutamide, were purchased from Toronto Research Chemicals (Toronto, Canada).

Techniques: Concentration Assay

Journal: Journal of pharmaceutical and biomedical analysis

Article Title: Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS

doi: 10.1016/j.jpba.2017.02.018

Figure Lengend Snippet: Stability of analytes under varying conditions

Article Snippet: 2.1 Chemicals and reagents Abiraterone, bicalutamide, N-desmethyl enzalutamide, enzalutamide, [D 4 ]-abiraterone, [D 4 ]-bicalutamide, were purchased from Toronto Research Chemicals (Toronto, Canada).

Techniques: Concentration Assay

Journal: Journal of pharmaceutical and biomedical analysis

Article Title: Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS

doi: 10.1016/j.jpba.2017.02.018

Figure Lengend Snippet: Treated patient plasma chromatograms of abiraterone (A), bicalutamide (B), enzalutamide (C), and N-desmethyl enzalutamide (D) with baseline separated analytes cross-talking into the respective MRM channels.

Article Snippet: 2.1 Chemicals and reagents Abiraterone, bicalutamide, N-desmethyl enzalutamide, enzalutamide, [D 4 ]-abiraterone, [D 4 ]-bicalutamide, were purchased from Toronto Research Chemicals (Toronto, Canada).

Techniques:

Journal: Investigational new drugs

Article Title: Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide.

doi: 10.1007/s10637-023-01407-x

Figure Lengend Snippet: Fig. 3 Endosomal recycling inhibitors synergise with the anti-androgen enzalutamide. A, B Clonogenic assays of LNCaP cells individually or dual treated with the indicated concentra- tions of enzalutamide and either PQ or MON for 7 days. Histo- gram indicates the surviving cells expressed as a percentage of the untreated control (n = 3). C, D Dose response curves of LNCaP 3D spheroids treated with enzalutamide alone (black) or combined with MON (green) or PQ (pink). Data representa- tive of 3 independent experi- ments

Article Snippet: Primaquine, lapatinib, enzalutamide and MTT were purchased from Carbosynth, UK.

Techniques: Control

Journal: Translational Cancer Research

Article Title: Analysis of novel enzalutamide-resistant cells: upregulation of testis-specific Y-encoded protein gene promotes the expression of androgen receptor splicing variant 7

doi: 10.21037/tcr-20-1463

Figure Lengend Snippet: Effect of enzalutamide on cell proliferation ( in vitro ) and tumor growth ( in vivo ) in LNCaP or SAS MDV No. 3–14 cells. (A) LNCaP and SAS MDV No. 3–14 cells were treated with different concentrations of enzalutamide in the presence of 0.1 nM (LNCaP) or 1 nM (SAS MDV No. 3–14) DHT. Consecutively, 3 (LNCaP) or 5 (SAS MDV No. 3–14) days after treatment with enzalutamide and DHT, cell growth was evaluated using the CellTiter-Glo assay. Data represent mean ± SD (N=6). ***, P<0.001 compared to vehicle control. # , P<0.05, ### , P<0.001 compared to DHT control. (B) Castrated male mice bearing LNCaP or SAS MDV No. 3–14 tumors were orally administered with vehicle or enzalutamide (10 mg/kg) daily. Data represent mean ± SE (N=10). ***, P<0.001; n.s., not significant compared to vehicle; DHT, dihydrotestosterone.

Article Snippet: Enzalutamide was synthesized in Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan).

Techniques: In Vitro, In Vivo, Glo Assay, Control